Clay Siegall is the Founder and Chief Executive Officer of Seattle Genetics. He is also the president of the company and also a member of its Board of Directors. Founded in 1998, Seattle Genetics is a firm which is focused on developing a broad range of clinical and preclinical drugs. Their target candidates are mainly victims of cancer and other autoimmune diseases. Dr. Siegall has provided excellent leadership in Seattle Genetics, making it one of the leading institutions on the fight against cancer.
Clay Siegall has also been significantly involved with the funding of Seattle Genetics. He helped to come up with over300 million us dollars in capital from both private and public funding. The firm has also been placed on the top of antibody technologies. Under the able leadership of Clay Siegall, the company has succeeded in getting FDA approval for their Antibody-drug conjugates (ADC)-technology based drugs.
Dr. Clay Siegall is a scientist by training and founded Seattle Genetics on principles of scientific foundations, drug development practices, and rigorous research. Clay is more focused on cancer therapies. His ADCs technology has helped to develop medicines which may change the future of cancer and autoimmune diseases patient’s future for good. He has nearly 20 years of vast experience in the cancer research as well as therapeutic drug development.
Before he co-founded Seattle Genetics, Dr. Clay worked with the Bristol-Myers Squibb Pharmaceutical Research Institute, National Institute of Health as well as the National Cancer Institute. Clay Siegall is also a member of the Board of Directors of Ultragenyx Pharmaceuticals, Mirna Therapeutics, Washington Roundtable and Alder pharmaceuticals. Due to his efforts towards cancer, Dr. Siegall is an important figure in the fight against cancer.
Clay Siegall is seen as a committed and competent professional. According to robsonvalleytimes.com, Seattle Genetics will employ more employees and expand its drug production to have more impact on patients all over the nation. Siegall has a great passion for helping patients; this makes his services efficient and centered more on the wellbeing of the patients.
Mirna Therapeutics, a top biotechnological firm that develops and commercializes microRNA (miRNA) therapeutics, appointed Dr. Clay B. Siegall as an external director and advisor of its Board of Directors on January 30, 2013. Mirna’s CEO and head, Dr. Paul Lammers, applauded Dr. Clay Siegall for agreeing to join the firm’s notable group of directors. He noted that Clay Siegall’s long-term pharmaceutical professional expertise and achievement in developing a prosperous oncology company would be instrumental for both Mirna team and its board.
About Mirna Therapeutics
Mirna Therapeutics has a dynamic portfolio of miRNA products developed by its scientists. The firm’s IP portfolio comprises of more than 300 miRNAs with applications in the specialty of oncology. Oncology-directed miRNAs consist of dominant suppressors of tumors in cancer including miR-34 and let-7 that have proven their ability to block the growth of tumor in a variety of pre-clinical animal studies. The Austin, Texas-based Mirna Therapeutics has received significant financing from both the State of Texas and private investors.
About Dr. Clay Siegall
Since co-founding Seattle Genetics in 1998, Dr. Clay has focused on building a dynamic line of antibody-based medications to solve unaddressed medical needs of people with cancer. In 2011, the company introduced its first certified and commercial product known as ADCETRIS. The firm has established strong connections with top pharmaceutical and biotechnology corporations in oncology. Dr. Clay Siegall has directed several capital-raising activities on behalf of Settle Genetics. These activities have generated over $675 million through IPO back in 2001, public, and private financing.
Academics and career
Dr. Clay is a talented and experienced scientist holding an undergrad in Zoology and a Ph.D. in Genetics. He is a proud alumnus of two prestigious universities: George Washington University and the University of Maryland. He started his research career at the National Cancer Institute back in 1988. He was also a senior researcher at the National Institutes of Health. He became part of Bristol-Myers Squibb Pharmaceutical Research Institute in 1991 and relinquished his influential position in 1997. He developed a passion for cancer research and decided to establish his firm (Seattle Genetics) in 1998 with a goal of leveraging antibody-based therapies to fight cancer.
Seattle Genetics is a biotechnology company that creates monoclonal antibody-based therapeutics to treat serious medical conditions. The company develops a broad variety of clinical and pre-clinical product candidates aimed at treating different types of cancer. It is also a leader in antibody technologies especially antibody-drug conjugate (ADC) platform.
For nearly 20 years, designed monoclonal antibodies have benefited cancer patients, people with autoimmune diseases and other acute medical conditions. Antibody-based therapies have advanced the treatment of cancer by targeting malignant cells and eliminating the damage to ordinary tissues. The outcome of this is better-tolerated therapies that can be used with chemotherapy to enhance patient outcomes without large increases in toxicities.
The firm is headquartered in Bothell, Washington and was founded in 1997. The company joins forces with other research companies and has made remarkable advancements in developing an effective treatment. It has agreements with several organizations such as Medarex, Bristol-Myers Squibb, and Genencor International. Seattle Genetics holds license agreements for its ADC technology with Eos Biotechnology, Celltech Group, and Genencor.
Since establishment, Seattle Genetics has grown and currently provides drugs to 50 countries around the world. As a result of the company’s increased collaborative efforts and effectiveness of their products, it has expanded to employ more than 600 staff. The company has achieved great milestones in the previous years such as initiating clinical trials of SGN-30, improving several clinical trials of SGN-15 and collaboration with other biotechnology companies. Dr. Clay Siegall has been integral to the company’s achievements.
Dr. Clay Siegall is the co-founder and CEO of Seattle Genetics. He is also the chairperson of the company’s board. In January 2013 he was appointed a member of the Board of Directors at Mirna Therapeutics. Dr. Siegall studied Zoology at the University of Maryland and holds a PhD in Genetics from the George Washington University. In 2013, the University of Maryland named Dr. Siegall the alumnus of the year for Math, Computer, and Natural Sciences.
Dr. Siegall is passionate about improving the lives of cancer patients and those with chronic illnesses. The scientist has built Seattle Genetics on a foundation of rigorous research, innovation, and drug development practices. Through Clay Siegall’s leadership, Seattle Genetics has seen substantial growth. Dr. Siegall has also helped the company raise more than $675 million to fund its research and training initiatives.
Read their reviews here: